TAS6417
- CLN-081
- Optical Purity: 0.99
- Soluble DMSO
- MF: C23H20N6O
- MW: 396.44
Description
TAS6417 is a novel EGFR inhibitor targeting EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR.
More Information
| Parent CAS No. | 1661854-97-2 |
|---|---|
| Chemical Name | (S)-N-(4-Amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | N1C(N)=C2C(C3C=NC4C=CC=CC=4C=3)=C3C(C)=C[C@H](NC(=O)C=C)CN3C2=NC=1 |&1:19,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C23H20N6O/c1-3-18(30)28-16-8-13(2)21-19(15-9-14-6-4-5-7-17(14)25-10-15)20-22(24)26-12-27-23(20)29(21)11-16/h3-10,12,16H,1,11H2,2H3,(H,28,30)(H2,24,26,27)/t16-/m0/s1 |
| InChiKey | MKCYPWYURWOKST-INIZCTEOSA-N |
| CID | 117918742 |
| Short Description | EGFR inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1760 | EGFR Inhibitor [879127-07-8] |
From $132.00 |
| 1986 | AST 1306 tosylate |
From $99.00 |
| 2342 | AZD9291 |
From $104.50 |
| 2563 | AZD3759 |
From $93.50 |
| 2680 | EAI045 |
From $115.50 |
| 2920 | Poziotinib |
From $104.50 |
| 2955 | NSC 228155 |
From $82.50 |
| 3040 | Abivertinib |
From $104.50 |
| 3192 | EMI48 |
From $132.00 |
| 3862 | BGB-283 |
From Inquiry |
| 4055 | Limertinib |
From $143.00 |
| 4074 | AZ5104 |
From Inquiry |
| 4130 | PELI1/EGFR disruptor S62 |
From $143.00 |
